Tanya Dorff, MD, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor T cells will improve outcomes.
Tanya Dorff, MD, a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor (CAR) T cells will improve outcomes.
During the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium, Dorff presented data around the use of engineered CAR T cells in patients with metastatic castration resistant prostate cancer. Considering that CAR T-cell therapy is a novel modality in prostate cancer, Dorff explains that achieving deep remissions with standard therapy and immunotherapy has not been successful in prostate cancer.
Moreover, there Dorff believe that T-cell technology may be a solution to the problem.
0:07 | Whereas immune checkpoint inhibitors have really changed prognosis in a major way for diseases like melanoma and renal cell, creating these durable remissions, you just don't see that same impact of standard immunotherapy like checkpoint inhibitors in prostate cancer.
0:25 | So, we have a lot of great treatments for prostate cancer, many different hormonal agents that are extremely powerful and are definitely improving our patients lives and then we have chemotherapy, radioactive particles. And there is immunotherapy with sipuleucel-t, but there's nothing yet that creates really durable remissions. And so, the hope is that T-cell technology is where we might start to achieve that.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen